Q: What are the characteristics of Bumrungrad International Hospital?
A: Established in 1980, it is a large general hospital with over 550 beds. It has approximately 4,800 employees.
It actively serves not only Thai citizens but also medical tourists. Of the 1 million annual visitors to the hospital, half are from outside of Thailand. The hospital focuses on providing services to the wealthy.
Q: How and why did Bumrungrad International Hospital choose the FonesVisuas Test?
A: Bumrungrad International Hospital has been providing cutting-edge and optimal medical care for each individual patient. One of the pillars of this is genetic testing, and the combination of FonesVisuas Test, which measures proteins and predicts the risk of disease within a few years, has been evaluated for its ability to provide even more personalized medical care and has led to its adoption.
Q: What is the analysis process? What is NEC’s role in this process?
A: Bumrungrad International Hospital performs blood draws on patients and sends the blood to FonesLife Corporatoin. FonesLife Corporation analyzes the blood (specimen) in its lab and provides test results as a report for disease risk prediction, while NEC conducts sales activities to hospitals and provides implementation support (handling inquiries before and after the service is provided).
Q: Describe the FonesVisuas Test.
A: This service provides information on “future disease prediction” and “current physical condition” by analyzing approximately 7,000 types of blood proteins. The service aims to change the future of “getting sick” by providing people with the opportunity to improve their lifestyle by knowing their own body condition and risks.
Q: Is the FonesVisuas Test the same as that provided by hospitals in Japan?
A: The testing service that can predict disease and provide information on the current state of the body is the same. In Japan, it is also offered as a concierge service that provides advice on what to do after receiving test results.
Q: What is the track record of providing FonesVisuas Test to Japanese hospitals?
A: As of April 2024, the service is provided to 72 medical institutions.
Q: NEC plans to expand sales mainly in APAC, but which countries are prioritized? What about countries and regions outside of APAC?
A: Currently, NEC has started providing services to a genetic testing company in Hong Kong and a clinic in Vietnam. NEC is considering expanding to Singapore and Malaysia in the future.
